Penumbra Announces Key Events at Society of NeuroInterventional Surgery 2016 Meeting

Penumbra 3D Trial Results to Be Presented at Late Breaking
Abstract Presentations Session

ALAMEDA, Calif.–(BUSINESS WIRE)–
Penumbra,
Inc
. (NYSE: PEN), a global interventional therapies company, today
announced its schedule of key events at the Society of
NeuroInterventional Surgery
(SNIS) 13th Annual Meeting to be
held July 25-28 in Boston, Massachusetts. These events include the
presentation of the results of the randomized controlled clinical trial
for the company’s next generation stent retriever, the Penumbra 3D
Revascularization Device.

Key Events

Late Breaking Abstract Session

The results of the randomized controlled clinical trial for the Penumbra
3D Revascularization Device will be presented during the Late Breaking
Abstract Presentations session on Wednesday, July 27 by Donald Frei, MD,
of Radiology Imaging Associates/Swedish Medical Center. The Late
Breaking Abstract Presentations session is scheduled for 11:35 a.m. ET
12:20 p.m. ET.

The Penumbra 3D Trial is a prospective, randomized controlled
non-inferiority study that compared the safety and efficacy of the
Penumbra 3D Revascularization Device used in conjunction with Penumbra
System aspiration devices with that of Penumbra System aspiration
devices alone. The Penumbra 3D Revascularization Device is approved for
investigational use only in the United States.

Industry Technology Luncheon Symposia

The company will feature its latest products at presentations to be held
Monday, July 25 at 1:30-1:45 p.m. ET; Wednesday, July 27 at 12:50-1:05
p.m. ET
; and Thursday, July 28 at 1:00-1:15 p.m. ET.

Stroke Awareness Event at Fenway Park

Penumbra will sponsor a public awareness event organized by The Joe
Niekro Foundation
together with The Bee Foundation on Tuesday, July 26
during the Boston Red Sox vs. Detroit Tigers baseball game at Fenway
Park
. The event will pay tribute to those lost to stroke and honor
survivors, with the aim to increase visibility and awareness of stroke
and its impact on patients and their families.

About Penumbra

Penumbra, Inc., headquartered in Alameda, California, is a global
interventional therapies company that designs, develops, manufactures
and markets innovative medical devices. The company has a broad
portfolio of products that address challenging medical conditions and
significant clinical needs across two major markets, neuro and
peripheral vascular. Penumbra sells its products to hospitals primarily
through its direct sales organization in the U.S., most of Europe,
Canada and Australia, and through distributors in select international
markets. Penumbra and the Penumbra logo are trademarks of Penumbra, Inc.

Forward-Looking Statements

Except for historical information, certain statements in this press
release are forward-looking in nature and are subject to risks,
uncertainties and assumptions about us. Our business and operations are
subject to a variety of risks and uncertainties and, consequently,
actual results may differ materially from those projected by any
forward-looking statements. Factors that could cause actual results to
differ from those projected include, but are not limited to: failure to
sustain or grow profitability or generate positive cash flows; failure
to effectively introduce and market new products; delays in product
introductions; significant competition; inability to further penetrate
our current customer base, expand our user base and increase the
frequency of use of our products by our customers; inability to achieve
or maintain satisfactory pricing and margins; manufacturing
difficulties; permanent write-downs or write-offs of our inventory;
product defects or failures; unfavorable outcomes in clinical trials;
inability to maintain our culture as we grow; fluctuations in foreign
currency exchange rates; and potential adverse regulatory actions. These
risks and uncertainties, as well as others, are discussed in greater
detail in our filings with the Securities and Exchange Commission,
including our Quarterly Reports on Form 10-Q and our Annual Report on
Form 10-K for the year ended December 31, 2015. There may be additional
risks of which we are not presently aware or that we currently believe
are immaterial which could have an adverse impact on our business. Any
forward-looking statements are based on our current expectations,
estimates and assumptions regarding future events and are applicable
only as of the dates of such statements. We make no commitment to revise
or update any forward-looking statements in order to reflect events or
circumstances that may change.

Source: Penumbra, Inc.

Source: Penumbra, Inc.

Merryman Communications

Betsy Merryman, 310-560-8176

betsy@merrymancommunications.com